Europe Is Spending €900 Million to Recruit American Scientists — and It Is Working

Forty-one of the forty-six scientists selected for France's inaugural "Choose France for Science" cohort were working in the United States when they applied. They did not leave because they wanted to live in Paris. They left because their NIH grants were frozen, their labs were being downsized, and a foreign government offered them €30 million in combined funding, no strings about indirect cost caps, and an explicit promise of scientific freedom.

France is not alone. The European Union, Canada, Australia, the United Kingdom, Germany, Denmark, the Netherlands, and Norway have all launched active recruitment campaigns targeting American researchers in the past year. The EU's "Choose Europe for Science" initiative alone has committed €900 million through 2027, and the European Research Council has doubled its relocation grants from €1 million to €2 million per researcher. Over 100 national and regional recruitment schemes are now active across all 27 EU member states.

This is not a hypothetical risk. The American scientific brain drain is underway, and the data says it is accelerating.

The Scale of Departure

A December 2025 report from the Information Technology and Innovation Foundation found that over 75 percent of U.S.-based scientists are considering leaving the country. Among early-career researchers — postdocs, junior faculty, and newly independent investigators — that number climbs to nearly 80 percent. The most commonly cited destinations are Europe and Canada.

These are not idle intentions. Since the start of 2025, the number of U.S.-based researchers actively seeking employment outside the country has risen 30 percent. Applications to European research positions from American institutions are at historic highs. The EU's EURAXESS portal — the largest job database for international research positions — is now processing more inquiries from U.S. applicants than from any other non-EU country.

The precedent is ominous. Between 2010 and 2021, an estimated 20,000 U.S.-based researchers of Chinese descent left the country in response to the Department of Justice's China Initiative, which subjected scientists to investigation and prosecution over alleged failure to disclose foreign ties. Many of those departures were permanent. The talent went to competitors, and the research output went with them.

What is happening now is broader in scope and less targeted in origin. The departures are not driven by one policy or one agency. They are driven by a convergence of funding uncertainty, workforce disruption, and a political environment that has made federal science careers unpredictable in ways that researchers have not experienced in the modern era.

What Europe Is Actually Offering

The EU's recruitment offensive is not a vague invitation. It is a structured, well-funded campaign with specific mechanisms designed to reduce friction for researchers considering a transatlantic move.

European Research Council grants are now worth up to €2 million each for Consolidator-level awards — the mid-career grants that most directly compete with NIH R01s and NSF CAREER awards. Unlike federal grants in the United States, ERC grants come with minimal reporting burden, no indirect cost negotiations, and five-year durations that provide genuine research stability. The ERC explicitly states that grants are "open to top researchers from anywhere in the world."

Marie Skłodowska-Curie Actions provide doctoral and postdoctoral funding that includes mobility allowances, family supplements, and institutional start-up packages. For early-career researchers watching U.S. postdoc salaries stagnate while NIH's MOSAIC program for diverse investigators was terminated, these fellowships offer a concrete alternative.

Practical relocation support rounds out the package. The Choose Europe initiative provides visa guidance, residence and work permits, diploma recognition, and intellectual property protections through a centralized support system. France's program goes further, offering laboratory setup funding, housing stipends, and dedicated administrative liaisons at host institutions.

The contrast with the current U.S. environment is stark. An American researcher applying for an R01 in March 2026 faces a system where NIH has posted 90 percent fewer funding notices than the prior year, where award timelines may stretch to 2027, and where $3.8 billion in existing grants have been canceled. A European researcher applying for an ERC grant faces a system that just increased its budget, doubled its relocation incentives, and is actively marketing to their American peers.

Why This Matters for the U.S. Grant Ecosystem

The loss of researchers to foreign institutions does not only affect the people who leave. It reshapes the competitive landscape for everyone who stays.

Study sections and review panels thin out. Federal peer review depends on a pool of active researchers willing to serve as reviewers. As senior investigators relocate abroad, the pool of available and eligible reviewers shrinks. NIH already struggles to staff study sections after losing 20 percent of its own workforce. Losing external reviewers to emigration compounds the problem.

Multi-PI collaborations fracture. Large-scale grants — P01 program projects, U54 cooperative agreements, multi-site clinical trials — depend on investigators at multiple U.S. institutions. When a key co-PI accepts a position in Munich or Marseille, the collaboration must either restructure or dissolve. Foreign-based investigators can sometimes participate in U.S. grants, but the administrative and compliance burden increases significantly.

Institutional rankings and indirect cost recovery decline. Universities depend on federal grant revenue not just for research operations but for the indirect cost reimbursements that fund libraries, research computing, compliance offices, and graduate student support. Every principal investigator who leaves for Europe takes their grant portfolio — and the associated indirect cost recovery — with them. For research-intensive universities already absorbing $1.7 billion in NIH funding withholds, each departure deepens the financial strain.

Innovation pipelines migrate. Discoveries made in European labs generate European patents, launch European startups, and strengthen European industrial ecosystems. The United States' dominance in translating basic research into commercial applications — the engine that built Silicon Valley, Boston's biotech corridor, and the Research Triangle — depends on the research happening here. When the researchers leave, the downstream economic value leaves with them.

The Countries Moving Fastest

Not all recruitment efforts are equal. Several countries have positioned themselves particularly aggressively.

France moved first and most visibly. The "Choose France for Science" program, launched in April 2025 with more than €30 million in initial funding, selected 46 laureates from 119 applications — with 41 arriving from U.S. institutions. A second cohort is expected later in 2026, and the program has already attracted attention disproportionate to its size because of the symbolic weight of American scientists choosing to leave.

Germany offers the Alexander von Humboldt Professorship, worth up to €5 million, as one of the world's most prestigious and generously funded international research awards. Applications from U.S. researchers have surged.

Canada has leveraged geographic proximity and cultural familiarity. The Canada Excellence Research Chairs program provides up to CAD $8 million over eight years, and the Canadian government has made expedited immigration processing available for researchers from disrupted U.S. programs.

The United Kingdom, despite its own post-Brexit research funding challenges, has positioned its £25 billion research budget as a destination for American scientists frustrated by the U.S. political climate, emphasizing the UK's tradition of research independence from political interference.

What Researchers Should Consider

For American scientists evaluating international offers, the calculus is more complex than salary-versus-salary.

Funding continuity matters. European grants offer longer durations and more predictable renewal cycles than the current U.S. system. But they also come with different overhead structures, different publication expectations, and different career trajectories. A five-year ERC grant is excellent; the question is what happens in year six when you are embedded in a system with different tenure norms and different institutional support structures.

Return pathways exist but are not guaranteed. U.S. institutions have historically welcomed returning researchers, but the current hiring freeze environment at many universities means there may not be positions to return to. Researchers considering a move should negotiate explicit return clauses or visiting appointments that maintain their U.S. institutional connections.

Staying competitive in the U.S. system is still possible. The agencies most affected by staffing losses — NIH and NSF — are not the only funders. DOE's Office of Science is running active solicitations. DOD's SBIR programs are restarting. State-level research funds in Massachusetts, Texas, New York, and California are mobilizing billions. Private foundations — from MacArthur to the Patrick J. McGovern Foundation, which recently committed $75.8 million across 149 grants — are increasing payouts. (Granted News)

The researchers most at risk of leaving are those whose entire funding portfolio depends on a single agency in a single country. The researchers most likely to stay are those who have diversified — across agencies, across mechanisms, across sectors — and who have the institutional backing to weather a prolonged period of uncertainty.

The Window Is Closing in Both Directions

Europe's recruitment campaigns are not permanent. The €900 million allocation runs through 2027. France's program is cohort-based, with finite slots. The ERC's doubled relocation grants are time-limited. For researchers considering a move, the most favorable terms are available now, not later.

For U.S. institutions trying to retain their faculty, the window is similarly narrow. Competitive retention packages — bridge funding, protected research time, startup supplements — are expensive but far cheaper than replacing a departed investigator and rebuilding their research program from scratch. Universities that wait for the federal system to stabilize before acting may find that their best people already made their decision.

The global competition for scientific talent has always existed. What changed in 2026 is that the United States stopped competing, and the rest of the world noticed. Platforms like Granted can help researchers scan both domestic and international opportunities while the traditional landscape resets — but the broader question of where American science happens next will be answered by the decisions individual researchers make in the months ahead.